Dr Barry Buckland Joins the Mucosis B.V. Supervisory Board

Dr Barry Buckland Joins the Mucosis B.V. Supervisory Board
Groningen, the Netherlands, 12 November 2010 -- Dutch biotechnology company Mucosis B.V. announced today that Dr Barry Buckland was elected to its Supervisory Board. Dr Buckland brings extensive experience in vaccine design and development.

From 1996 to 2009, Dr Buckland was Vice President, BioProcess R&D at Merck & Co, Inc. He built the unit and was responsible for process development for 14 new commercial products, including 10 new vaccines. More recently Dr Buckland has been a consultant to Hilleman Laboratories, the vaccine venture established between Merck and The Wellcome Trust. Dr Buckland received many professional and academic honors, including the 2008 Marvin Johnson Award from the American Chemical Society for lifetime contribution to biotechnology. He has authored 77 scientific papers.

"I am delighted to have this opportunity to contribute to the success of Mucosis" commented Dr Buckland. "The Company's mucosal immunity platform will have many applications in developing superior vaccines".

John Lambert, Chairman of Mucosis added: "Barry's insight and experience stem from being involved in the design, development and commercialization of many of today's blockbuster vaccines. He will be invaluable to Mucosis".

 

For further information please contact:

Govert Schouten CEO Mucosis +31 (6) 55320948 [email protected] www.mucosis.com

 

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.